CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

The Morel Company

A new, innovative product that allows a single caregiver to reposition a patient up in bed in less than ten seconds with the simple push of a button. Learn more here.

uniPHARM Wholesale Drugs

uniPHARM Wholesale Drugs Ltd. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascend SpecialtyRx

Ascend SpecialtyRx is a Port Washington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PDO Max

Vascular Technology

Vascular Technology Incorporated is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.